<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">34902552</PMID><DateCompleted><Year>2022</Year><Month>04</Month><Day>07</Day></DateCompleted><DateRevised><Year>2023</Year><Month>01</Month><Day>21</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1095-953X</ISSN><JournalIssue CitedMedium="Internet"><Volume>162</Volume><PubDate><Year>2022</Year><Month>Jan</Month></PubDate></JournalIssue><Title>Neurobiology of disease</Title><ISOAbbreviation>Neurobiol Dis</ISOAbbreviation></Journal><ArticleTitle>KLF15 overexpression in myocytes fails to ameliorate ALS-related pathology or extend the lifespan of SOD1G93A mice.</ArticleTitle><Pagination><StartPage>105583</StartPage><MedlinePgn>105583</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.nbd.2021.105583</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0969-9961(21)00332-6</ELocationID><Abstract><AbstractText>Amyotrophic Lateral Sclerosis (ALS) is a currently incurable disease that causes progressive motor neuron loss, paralysis and death. Skeletal muscle pathology occurs early during the course of ALS. It is characterized by impaired mitochondrial biogenesis, metabolic dysfunction and deterioration of the neuromuscular junction (NMJ), the synapse through which motor neurons communicate with muscles. Therefore, a better understanding of the molecules that underlie this pathology may lead to therapies that slow motor neuron loss and delay ALS progression. Kruppel Like Factor 15 (KLF15) has been identified as a transcription factor that activates alternative metabolic pathways and NMJ maintenance factors, including Fibroblast Growth Factor Binding Protein 1 (FGFBP1), in skeletal myocytes. In this capacity, KLF15 has been shown to play a protective role in Duchenne muscular dystrophy (DMD) and spinal muscular atrophy (SMA), however its role in ALS has not been evaluated. Here, we examined whether muscle-specific KLF15 overexpression promotes the health of skeletal muscles and NMJs in the SOD1<sup>G93A</sup> ALS mouse model. We show that muscle-specific KLF15 overexpression did not elicit a significant beneficial effect on skeletal muscle atrophy, NMJ health, motor function, or survival in SOD1<sup>G93A</sup> ALS mice. Our findings suggest that, unlike in mouse models of DMD and SMA, KLF15 overexpression has a minimal impact on ALS disease progression in SOD1<sup>G93A</sup> mice.</AbstractText><CopyrightInformation>Copyright &#xa9; 2021 The Authors. Published by Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Massopust</LastName><ForeName>Ryan</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Molecular Biology, Cell Biology and Biochemistry, Brown University, Providence, RI, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Juros</LastName><ForeName>Devin</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Molecular Biology, Cell Biology and Biochemistry, Brown University, Providence, RI, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shapiro</LastName><ForeName>Dillon</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Molecular Biology, Cell Biology, &amp; Biochemistry Graduate Program, Brown University, Providence, RI, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lopes</LastName><ForeName>Mikayla</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Molecular Biology, Cell Biology and Biochemistry, Brown University, Providence, RI, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Haldar</LastName><ForeName>Saptarsi M</ForeName><Initials>SM</Initials><AffiliationInfo><Affiliation>Gladstone Institutes, San Francisco, CA, USA; Department of Medicine, Cardiology Division, UCSF School of Medicine, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Taetzsch</LastName><ForeName>Thomas</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Molecular Biology, Cell Biology and Biochemistry, Brown University, Providence, RI, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Valdez</LastName><ForeName>Gregorio</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Molecular Biology, Cell Biology and Biochemistry, Brown University, Providence, RI, USA; Center for Translational Neuroscience, Robert J. and Nancy D. Carney Institute for Brain Science and Brown Institute for Translational Science, Brown University, Providence, RI, USA; Department of Neurology, Warren Alpert Medical School of Brown University, Providence, United States. Electronic address: gregorio_valdez@brown.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 AG055545</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R21 NS106313</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R56 AG051501</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T32 AG041688</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>12</Month><Day>11</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Neurobiol Dis</MedlineTA><NlmUniqueID>9500169</NlmUniqueID><ISSNLinking>0969-9961</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C489453">Fgfbp1 protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D036341">Intercellular Signaling Peptides and Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C467418">Klf15 protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D051741">Kruppel-Like Transcription Factors</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 1.15.1.1</RegistryNumber><NameOfSubstance UI="D000072105">Superoxide Dismutase-1</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D036341" MajorTopicYN="N">Intercellular Signaling Peptides and Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051741" MajorTopicYN="Y">Kruppel-Like Transcription Factors</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008136" MajorTopicYN="N">Longevity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009046" MajorTopicYN="N">Motor Neurons</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D032342" MajorTopicYN="N">Muscle Cells</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018482" MajorTopicYN="N">Muscle, Skeletal</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009469" MajorTopicYN="N">Neuromuscular Junction</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000072105" MajorTopicYN="N">Superoxide Dismutase-1</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">ALS</Keyword><Keyword MajorTopicYN="N">FGFBP1</Keyword><Keyword MajorTopicYN="N">KLF15</Keyword><Keyword MajorTopicYN="N">NMJ</Keyword></KeywordList><CoiStatement>Competing Interest Disclosure. Saptarsi M. Haldar is an executive, officer and shareholder of Amgen and a scientific founder and shareholder of Tenaya Therapeutics.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>6</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2021</Year><Month>11</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>12</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>12</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>4</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>12</Month><Day>13</Day><Hour>20</Hour><Minute>16</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34902552</ArticleId><ArticleId IdType="mid">NIHMS1765702</ArticleId><ArticleId IdType="pmc">PMC8750438</ArticleId><ArticleId IdType="doi">10.1016/j.nbd.2021.105583</ArticleId><ArticleId IdType="pii">S0969-9961(21)00332-6</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Kim G, Gautier O, Tassoni-Tsuchida E, Ma XR, Gitler AD, ALS Genetics: Gains, Losses, and Implications for Future Therapies, Neuron. 108 (2020) 822&#x2013;842. doi:10.1016/j.neuron.2020.08.022.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2020.08.022</ArticleId><ArticleId IdType="pmc">PMC7736125</ArticleId><ArticleId IdType="pubmed">32931756</ArticleId></ArticleIdList></Reference><Reference><Citation>Loeffler JP, Picchiarelli G, Dupuis L, Gonzalez De Aguilar JL, The role of skeletal muscle in amyotrophic lateral sclerosis, in: Brain Pathol, Blackwell Publishing Ltd, 2016: pp. 227&#x2013;236. doi:10.1111/bpa.12350.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/bpa.12350</ArticleId><ArticleId IdType="pmc">PMC8029271</ArticleId><ArticleId IdType="pubmed">26780251</ArticleId></ArticleIdList></Reference><Reference><Citation>Moloney EB, de Winter F, Verhaagen J, ALS as a distal axonopathy: molecular mechanisms affecting neuromuscular junction stability in the presymptomatic stages of the disease., Front. Neurosci. 8 (2014) 252. doi:10.3389/fnins.2014.00252.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnins.2014.00252</ArticleId><ArticleId IdType="pmc">PMC4132373</ArticleId><ArticleId IdType="pubmed">25177267</ArticleId></ArticleIdList></Reference><Reference><Citation>Killian JM, Wilfong AA, Burnett L, Appel SH, Boland D, Decremental motor responses to repetitive nerve stimulation in ALS, Muscle Nerve. 17 (1994) 747&#x2013;754. doi:10.1002/mus.880170708.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mus.880170708</ArticleId><ArticleId IdType="pubmed">8008001</ArticleId></ArticleIdList></Reference><Reference><Citation>Fischer LR, Culver DG, Tennant P, Davis AA, Wang M, Castellano-Sanchez A, Khan J, Polak MA, Glass JD, Amyotrophic lateral sclerosis is a distal axonopathy: evidence in mice and man, Exp. Neurol. 185 (2004) 232&#x2013;240. doi:10.1016/J.EXPNEUROL.2003.10.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/J.EXPNEUROL.2003.10.004</ArticleId><ArticleId IdType="pubmed">14736504</ArticleId></ArticleIdList></Reference><Reference><Citation>Pun S, Santos AF, Saxena S, Xu L, Caroni P, Selective vulnerability and pruning of phasic motoneuron axons in motoneuron disease alleviated by CNTF, Nat. Neurosci. 9 (2006) 408&#x2013;419. doi:10.1038/nn1653.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nn1653</ArticleId><ArticleId IdType="pubmed">16474388</ArticleId></ArticleIdList></Reference><Reference><Citation>Dobrowolny G, Aucello M, Rizzuto E, Beccafico S, Mammucari C, Boncompagni S, Belia S, Wannenes F, Nicoletti C, Del Prete Z, Rosenthal N, Molinaro M, Protasi F, Fan&#xf2; G, Sandri M, Musar&#xf2; A, Skeletal Muscle Is a Primary Target of SOD1G93A-Mediated Toxicity, Cell Metab. 8 (2008) 425&#x2013;436. doi:10.1016/j.cmet.2008.09.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cmet.2008.09.002</ArticleId><ArticleId IdType="pubmed">19046573</ArticleId></ArticleIdList></Reference><Reference><Citation>Wong M, Martin LJ, Skeletal muscle-restricted expression of human SOD1 causes motor neuron degeneration in transgenic mice, Hum. Mol. Genet. 19 (2010) 2284&#x2013;2302. doi:10.1093/hmg/ddq106.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddq106</ArticleId><ArticleId IdType="pmc">PMC2865380</ArticleId><ArticleId IdType="pubmed">20223753</ArticleId></ArticleIdList></Reference><Reference><Citation>Martin LJ, Wong M, Skeletal Muscle-Restricted Expression of Human SOD1 in Transgenic Mice Causes a Fatal ALS-Like Syndrome, Front. Neurol. 11 (2020). doi:10.3389/fneur.2020.592851.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fneur.2020.592851</ArticleId><ArticleId IdType="pmc">PMC7767933</ArticleId><ArticleId IdType="pubmed">33381076</ArticleId></ArticleIdList></Reference><Reference><Citation>Myoung JC, Suh YL, Ultrastructural changes of mitochondria in the skeletal muscle of patients with amyotrophic lateral sclerosis, Ultrastruct. Pathol. 26 (2002) 3&#x2013;7. doi:10.1080/01913120252934260.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/01913120252934260</ArticleId><ArticleId IdType="pubmed">12028652</ArticleId></ArticleIdList></Reference><Reference><Citation>Echaniz-Laguna A, Zoll J, Ponsot E, N&#x2019;Guessan B, Tranchant C, Loeffler JP, Lampert E, Muscular mitochondrial function in amyotrophic lateral sclerosis is progressively altered as the disease develops: A temporal study in man, Exp. Neurol. 198 (2006) 25&#x2013;30. doi:10.1016/j.expneurol.2005.07.020.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.expneurol.2005.07.020</ArticleId><ArticleId IdType="pubmed">16126198</ArticleId></ArticleIdList></Reference><Reference><Citation>Krasnianski A, Deschauer M, Neudecker S, Gellerich FN, M&#xfc;ller T, Schoser BG, Krasnianski M, Zierz S, Mitochondrial changes in skeletal muscle in amyotrophic lateral sclerosis and other neurogenic atrophies, Brain. 128 (2005) 1870&#x2013;1876. doi:10.1093/brain/awh540.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awh540</ArticleId><ArticleId IdType="pubmed">15901649</ArticleId></ArticleIdList></Reference><Reference><Citation>Vielhaber S, Winkler K, Kirches E, Kunz D, B&#xfc;chner M, Feistner H, Elger CE, Ludolph AC, Riepe MW, Kunz WS, Visualization of defective mitochondrial function in skeletal muscle fibers of patients with sporadic amyotrophic lateral sclerosis, J. Neurol. Sci. 169 (1999) 133&#x2013;139. doi:10.1016/S0022-510X(99)00236-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0022-510X(99)00236-1</ArticleId><ArticleId IdType="pubmed">10540022</ArticleId></ArticleIdList></Reference><Reference><Citation>Dupuis L, Oudart H, Ren&#xe9; F, Gonzalez De Aguilar JL, Loeffler JP, Evidence for defective energy homeostasis in amyotrophic lateral sclerosis: Benefit of a high-energy diet in a transgenic mouse model, Proc. Natl. Acad. Sci. U. S. A. 101 (2004) 11159&#x2013;11164. doi:10.1073/pnas.0402026101.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0402026101</ArticleId><ArticleId IdType="pmc">PMC503756</ArticleId><ArticleId IdType="pubmed">15263088</ArticleId></ArticleIdList></Reference><Reference><Citation>Palamiuc L, Schlagowski A, Ngo ST, Vernay A, Dirrig&#x2010;Grosch S, Henriques A, Boutillier A, Zoll J, Echaniz&#x2010;Laguna A, Loeffler J, Ren&#xe9; F, A metabolic switch toward lipid use in glycolytic muscle is an early pathologic event in a mouse model of amyotrophic lateral sclerosis, EMBO Mol. Med. 7 (2015) 526&#x2013;546. doi:10.15252/emmm.201404433.</Citation><ArticleIdList><ArticleId IdType="doi">10.15252/emmm.201404433</ArticleId><ArticleId IdType="pmc">PMC4492815</ArticleId><ArticleId IdType="pubmed">25820275</ArticleId></ArticleIdList></Reference><Reference><Citation>Steyn FJ, Li R, Kirk SE, Tefera TW, Xie TY, Tracey TJ, Kelk D, Wimberger E, Garton FC, Roberts L, Chapman SE, Coombes JS, Leevy WM, Ferri A, Valle C, Ren&#xe9; F, Loeffler J-P, McCombe PA, Henderson RD, Ngo ST, Altered skeletal muscle glucose-fatty acid flux in amyotrophic lateral sclerosis, Brain Commun. 2 (2020). doi:10.1093/braincomms/fcaa154.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/braincomms/fcaa154</ArticleId><ArticleId IdType="pmc">PMC7677608</ArticleId><ArticleId IdType="pubmed">33241210</ArticleId></ArticleIdList></Reference><Reference><Citation>Dobrowolny G, Lepore E, Martini M, Barberi L, Nunn A, Scicchitano BM, Musar&#xf2; A, Metabolic changes associated with muscle expression of SOD1G93A, Front. Physiol. 9 (2018). doi:10.3389/fphys.2018.00831.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fphys.2018.00831</ArticleId><ArticleId IdType="pmc">PMC6048270</ArticleId><ArticleId IdType="pubmed">30042688</ArticleId></ArticleIdList></Reference><Reference><Citation>Vandoorne T, De Bock K, Van Den Bosch L, Energy metabolism in ALS: an underappreciated opportunity?, Acta Neuropathol. 135 (2018) 489&#x2013;509. doi:10.1007/s00401-018-1835-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-018-1835-x</ArticleId><ArticleId IdType="pmc">PMC5978930</ArticleId><ArticleId IdType="pubmed">29549424</ArticleId></ArticleIdList></Reference><Reference><Citation>Argil&#xe9;s JM, Campos N, Lopez-Pedrosa JM, Rueda R, Rodriguez-Ma&#xf1;as L, Skeletal Muscle Regulates Metabolism via Interorgan Crosstalk: Roles in Health and Disease, J. Am. Med. Dir. Assoc. 17 (2016) 789&#x2013;796. doi:10.1016/j.jamda.2016.04.019.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jamda.2016.04.019</ArticleId><ArticleId IdType="pubmed">27324808</ArticleId></ArticleIdList></Reference><Reference><Citation>Haldar SM, Jeyaraj D, Anand P, Zhu H, Lu Y, Prosdocimo DA, Eapen B, Kawanami D, Okutsu M, Brotto L, Fujioka H, Kerner J, Rosca MG, McGuinness OP, Snow RJ, Russell AP, Gerber AN, Bai X, Yan Z, Nosek TM, Brotto M, Hoppel CL, Jain MK, Kruppel-like factor 15 regulates skeletal muscle lipid flux and exercise adaptation, Proc. Natl. Acad. Sci. U. S. A. 109 (2012) 6739&#x2013;6744. doi:10.1073/pnas.1121060109.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1121060109</ArticleId><ArticleId IdType="pmc">PMC3340075</ArticleId><ArticleId IdType="pubmed">22493257</ArticleId></ArticleIdList></Reference><Reference><Citation>Haldar SM, Ibrahim OA, Jain MK, Kruppel-like Factors (KLFs) in muscle biology, J. Mol. Cell. Cardiol. 43 (2007) 1&#x2013;10. doi:10.1016/j.yjmcc.2007.04.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.yjmcc.2007.04.005</ArticleId><ArticleId IdType="pmc">PMC2743293</ArticleId><ArticleId IdType="pubmed">17531262</ArticleId></ArticleIdList></Reference><Reference><Citation>Morrison-Nozik A, Anand P, Zhu H, Duan Q, Sabeh M, Prosdocimo DA, Lemieux ME, Nordsborg N, Russell AP, MacRae CA, Gerber AN, Jain MK, Haldar SM, Glucocorticoids enhance muscle endurance and ameliorate Duchenne muscular dystrophy through a defined metabolic program., Proc. Natl. Acad. Sci. U. S. A. 112 (2015) E6780&#x2013;9. doi:10.1073/pnas.1512968112.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1512968112</ArticleId><ArticleId IdType="pmc">PMC4679037</ArticleId><ArticleId IdType="pubmed">26598680</ArticleId></ArticleIdList></Reference><Reference><Citation>Fan L, Sweet DR, Prosdocimo DA, Vinayachandran V, Chan ER, Zhang R, Ilkayeva O, Lu Y, Keerthy KS, Booth CE, Newgard CB, Jain MK, Muscle Kr&#xfc;ppel-like factor 15 regulates lipid flux and systemic metabolic homeostasis, J. Clin. Invest. 131 (2021). doi:10.1172/JCI139496.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI139496</ArticleId><ArticleId IdType="pmc">PMC7880311</ArticleId><ArticleId IdType="pubmed">33586679</ArticleId></ArticleIdList></Reference><Reference><Citation>Walter LM, Deguise MO, Meijboom KE, Betts CA, Ahlskog N, van Westering TLE, Hazell G, McFall E, Kordala A, Hammond SM, Abendroth F, Murray LM, Shorrock HK, Prosdocimo DA, Haldar SM, Jain MK, Gillingwater TH, Claus P, Kothary R, Wood MJA, Bowerman M, Interventions Targeting Glucocorticoid-Kr&#xfc;ppel-like Factor 15-Branched-Chain Amino Acid Signaling Improve Disease Phenotypes in Spinal Muscular Atrophy Mice, EBioMedicine. 31 (2018) 226&#x2013;242. doi:10.1016/j.ebiom.2018.04.024.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ebiom.2018.04.024</ArticleId><ArticleId IdType="pmc">PMC6013932</ArticleId><ArticleId IdType="pubmed">29735415</ArticleId></ArticleIdList></Reference><Reference><Citation>Ahlskog N, Hayler D, Krueger A, Kubinski S, Claus P, Hammond SM, Wood MJA, Y&#xe1;&#xf1;ez-Mu&#xf1;oz RJ, Bowerman M, Muscle overexpression of Klf15 via an AAV8-Spc5-12 construct does not provide benefits in spinal muscular atrophy mice, Gene Ther. 27 (2020) 505&#x2013;515. doi:10.1038/s41434-020-0146-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41434-020-0146-8</ArticleId><ArticleId IdType="pmc">PMC7674152</ArticleId><ArticleId IdType="pubmed">32313099</ArticleId></ArticleIdList></Reference><Reference><Citation>Taetzsch T, Tenga MJ, Valdez G, Muscle Fibers Secrete FGFBP1 to Slow Degeneration of Neuromuscular Synapses during Aging and Progression of ALS., J. Neurosci. 37 (2017) 70&#x2013;82. doi:10.1523/JNEUROSCI.2992-16.2017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.2992-16.2017</ArticleId><ArticleId IdType="pmc">PMC5214636</ArticleId><ArticleId IdType="pubmed">28053031</ArticleId></ArticleIdList></Reference><Reference><Citation>Valdez G, Tapia JC, Lichtman JW, Fox MA, Sanes JR, Shared resistance to aging and ALS in neuromuscular junctions of specific muscles., PLoS One. 7 (2012) e34640. doi:10.1371/journal.pone.0034640.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0034640</ArticleId><ArticleId IdType="pmc">PMC3317643</ArticleId><ArticleId IdType="pubmed">22485182</ArticleId></ArticleIdList></Reference><Reference><Citation>Gurney ME, Pu H, Chiu AY, Dal Canto MC, Polchow CY, Alexander DD, Caliendo J, Hentati A, Kwon YW, Deng HX, Motor neuron degeneration in mice that express a human Cu,Zn superoxide dismutase mutation., Science. 264 (1994) 1772&#x2013;5. http://www.ncbi.nlm.nih.gov/pubmed/8209258 (accessed December 9, 2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">8209258</ArticleId></ArticleIdList></Reference><Reference><Citation>Mouton PR, Unbiased stereology : a concise guide/, Johns Hopkins University Press, Baltimore: :, 2011.</Citation></Reference><Reference><Citation>Aartsma-Rus A, van Putten M, Assessing functional performance in the Mdx mouse model, J. Vis. Exp. 85 (2014) 51303. doi:10.3791/51303.</Citation><ArticleIdList><ArticleId IdType="doi">10.3791/51303</ArticleId><ArticleId IdType="pmc">PMC4158772</ArticleId><ArticleId IdType="pubmed">24747372</ArticleId></ArticleIdList></Reference><Reference><Citation>Marcuzzo S, Zucca I, Mastropietro A, de Rosbo NK, Cavalcante P, Tartari S, Bonanno S, Preite L, Mantegazza R, Bernasconi P, Hind limb muscle atrophy precedes cerebral neuronal degeneration in G93A-SOD1 mouse model of amyotrophic lateral sclerosis: A longitudinal MRI study, Exp. Neurol. 231 (2011) 30&#x2013;37. doi:10.1016/j.expneurol.2011.05.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.expneurol.2011.05.007</ArticleId><ArticleId IdType="pubmed">21620832</ArticleId></ArticleIdList></Reference><Reference><Citation>Hegedus J, Putman CT, Tyreman N, Gordon T, Preferential motor unit loss in the SOD1 G93A transgenic mouse model of amyotrophic lateral sclerosis, J. Physiol. 586 (2008) 3337&#x2013;3351. doi:10.1113/jphysiol.2007.149286.</Citation><ArticleIdList><ArticleId IdType="doi">10.1113/jphysiol.2007.149286</ArticleId><ArticleId IdType="pmc">PMC2538809</ArticleId><ArticleId IdType="pubmed">18467368</ArticleId></ArticleIdList></Reference><Reference><Citation>Hegedus J, Putman CT, Gordon T, Time course of preferential motor unit loss in the SOD1G93A mouse model of amyotrophic lateral sclerosis, Neurobiol. Dis. 28 (2007) 154&#x2013;164. doi:10.1016/j.nbd.2007.07.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nbd.2007.07.003</ArticleId><ArticleId IdType="pubmed">17766128</ArticleId></ArticleIdList></Reference><Reference><Citation>Tintignac LA, Brenner HR, R&#xfc;egg MA, Mechanisms regulating neuromuscular junction development and function and causes of muscle wasting, Physiol. Rev. 95 (2015) 809&#x2013;852. doi:10.1152/physrev.00033.2014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1152/physrev.00033.2014</ArticleId><ArticleId IdType="pubmed">26109340</ArticleId></ArticleIdList></Reference><Reference><Citation>Kira Y, Nishikawa M, Ochi A, Sato E, Inoue M, L-Carnitine suppresses the onset of neuromuscular degeneration and increases the life span of mice with familial amyotrophic lateral sclerosis, Brain Res. 1070 (2006) 206&#x2013;214. doi:10.1016/j.brainres.2005.11.052.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.brainres.2005.11.052</ArticleId><ArticleId IdType="pubmed">16412993</ArticleId></ArticleIdList></Reference><Reference><Citation>Beghi E, Pupillo E, Bonito V, Buzzi P, Caponnetto C, Chi&#xf2; A, Corbo M, Giannini F, Inghilleri M, La Bella V, Logroscino G, Lorusso L, Lunetta C, Mazzini L, Messina P, Mora G, Perini M, Quadrelli ML, Silani V, Simone IL, Tremolizzo L, Samarelli V, Tortelli R, D&#x2019;Errico E, Merello M, Tavernelli F, Mancardi GL, Mascolo M, Bendotti C, Buratti M, Floriani I, Giordano L, Giussani G, Maderna L, Maestri E, Marinou K, Mennini T, Messina S, Morelli C, Papetti L, Rizzo A, Ticozzi N, Verde F, Ferrarese C, Marzorati L, Testa L, Valentino F, Frasca V, Giacomelli E, Casa S, Malentacchi M, Calvo A, Cammarosano S, Moglia C, Cavallo E, Fuda G, Randomized double-blind placebo-controlled trial of acetyl-L-carnitine for ALS, Amyotroph. Lateral Scler. Front. Degener. 14 (2013) 397&#x2013;405. doi:10.3109/21678421.2013.764568.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/21678421.2013.764568</ArticleId><ArticleId IdType="pubmed">23421600</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang JW, Kim S-M, Kim H-J, Kim J-E, Park KS, Kim S-H, Lee K-W, Sung J-J, Hypolipidemia in Patients with Amyotrophic Lateral Sclerosis: A Possible Gender Difference?, J. Clin. Neurol. 9 (2013) 125. doi:10.3988/jcn.2013.9.2.125.</Citation><ArticleIdList><ArticleId IdType="doi">10.3988/jcn.2013.9.2.125</ArticleId><ArticleId IdType="pmc">PMC3633190</ArticleId><ArticleId IdType="pubmed">23626651</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim S-M, Kim H, Kim J-E, Park KS, Sung J-J, Kim SH, Lee K-W, Amyotrophic Lateral Sclerosis Is Associated with Hypolipidemia at the Presymptomatic Stage in Mice, PLoS One. 6 (2011) e17985. doi:10.1371/journal.pone.0017985.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0017985</ArticleId><ArticleId IdType="pmc">PMC3064597</ArticleId><ArticleId IdType="pubmed">21464953</ArticleId></ArticleIdList></Reference><Reference><Citation>Fergani A, Oudart H, De Aguilar JLG, Fricker B, Ren&#xe9; F, Hocquette JF, Meininger V, Dupuis L, Loeffler JP, Increased peripheral lipid clearance in an animal model of amyotrophic lateral sclerosis, J. Lipid Res. 48 (2007) 1571&#x2013;1580. doi:10.1194/jlr.M700017-JLR200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1194/jlr.M700017-JLR200</ArticleId><ArticleId IdType="pmc">PMC1974855</ArticleId><ArticleId IdType="pubmed">17438338</ArticleId></ArticleIdList></Reference><Reference><Citation>O&#x2019;Reilly &#xc9;J, Wang H, Weisskopf MG, Fitzgerald KC, Falcone G, McCullough ML, Thun M, Park Y, Kolonel LN, Ascherio A, Premorbid body mass index and risk of amyotrophic lateral sclerosis, Amyotroph. Lateral Scler. Front. Degener. 14 (2013) 205&#x2013;211. doi:10.3109/21678421.2012.735240.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/21678421.2012.735240</ArticleId><ArticleId IdType="pmc">PMC3615420</ArticleId><ArticleId IdType="pubmed">23134505</ArticleId></ArticleIdList></Reference><Reference><Citation>Ludolph AC, Dorst J, Dreyhaupt J, Weishaupt JH, Kassubek J, Weiland U, Meyer T, Petri S, Hermann A, Emmer A, Grosskreutz J, Grehl T, Zeller D, Boentert M, Schrank B, Prudlo J, Winkler AS, Gorbulev S, Roselli F, Schuster J, Dupuis L, Effect of High-Caloric Nutrition on Survival in Amyotrophic Lateral Sclerosis, Ann. Neurol. 87 (2020) 206&#x2013;216. doi:10.1002/ana.25661.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.25661</ArticleId><ArticleId IdType="pubmed">31849093</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>